Author

Melinda S. Y. Tan

Observed name: Melinda Tan

Institution: Mayo Clinic

Observed institutions: Mayo Clinic, National University of Singapore, Duke-NUS Medical School

ORCID: 0000-0003-1690-1447

Observed ORCID: 0000-0003-1690-1447

OpenAlex ID: A5103478519

Mismatch Repair Deficiency Screening via Immunohistochemical Staining in Young Asians with Colorectal Cancers

2013 · Min‐Hoe Chew, Poh‐Koon Koh, et al. · World Journal of Surgery · 14

Investigating the association between peak post-infusion absolute lymphocyte count (ALC) and delayed toxicity in myeloma (MM) patients (pts) receiving cilta-cel.

2025 · Kenneth J.C. Lim, Ricardo Daniel Parrondo, et al. · Journal of Clinical Oncology · 7

AL amyloidosis: a real-world experience with CAR T-cell therapy

2025 · Melinda S. Y. Tan, Rahma Warsame, et al. · Blood Advances · 6

Clinical course, risk factors, and therapeutic response in multiple myeloma with central nervous system involvement

2026 · Alexander Xiao, Saurabh Zanwar, et al. · Blood Advances · 1

Subsequent primary malignancies after CAR-T therapy: A study from the US multiple myeloma immunotherapy consortium

2025 · Eli Zolotov, Noa Biran, et al. · Blood · 1

Assessment For Circulating Plasma Cell Enhances R2-ISS in Newly Diagnosed Multiple Myeloma

2025 · Arwa Bohra, Melinda Tan, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

PA-130 Dasatinib and Quercetin in Patients with Relapsed, Refractory Multiple Myeloma Receiving CAR-T Therapy: First Report from the Safety Run-in of the Phase II DART Trial

2026 · Christoph Schaefers, Melinda Tan, et al. · Clinical Lymphoma Myeloma & Leukemia

OA-41 Mitigating Cilta-cel-Associated Delayed Neurotoxicity in Patients with High Lymphocyte Expansion: A Prospective Observational Comparative Study of Prophylactic Cyclophosphamide

2026 · Christoph Schaefers, Melinda Tan, et al. · Clinical Lymphoma Myeloma & Leukemia

PA-492 The Role of Prehabilitation in Individuals Undergoing CAR-T Therapy for Relapsed or Refractory Multiple Myeloma

2026 · Shannon Strader, Jenny Bradt, et al. · Clinical Lymphoma Myeloma & Leukemia

PA-101 Clinicobiological Characteristics, Contemporary Outcomes and Real-World Treatment Patterns in AL Amyloidosis: A Tertiary Center Experience from Asia

2026 · Aditi Manjeri, Melinda Tan, et al. · Clinical Lymphoma Myeloma & Leukemia

Cardiac Amyloidosis AI‐ECG Model is Useful in Predicting Outcomes in Multiple Myeloma Patients Without Amyloidosis Undergoing Autologous Stem Cell Transplant

2026 · Melinda S. Y. Tan, Morie A. Gertz, et al. · Advances in Hematology

Outcomes of CAR-T Cell Therapy in Patients with AL Amyloidosis

2025 · Melinda Tan, Rahma Warsame, et al. · Clinical Lymphoma Myeloma & Leukemia

Works count: 12

Citation count: 30

H-index: 3

I10-index: 1